Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press86410.17650/1994-4098-2021-17-3-59-68MAMMOLOGY. REVIEWSМАММОЛОГИЯ. ОБЗОРНЫЕ СТАТЬИ10 years of success achieved by eribulin while treating HER2-negative mBC: from randomized studies to routine practice10 лет успеха эрибулина в лечении HER2-отрицательного мРМЖ: от рандомизированных исследований к рутинной практикеhttps://orcid.org/0000-0002-1124-6802KolyadinaI. V.КолядинаИ. В.
Russian Federation

2/1 Barrikadnaya St., Moscow 125993; 4 Akademika Oparina St., Moscow 117198

125993 Москва, ул. Баррикадная, 2/1, стр. 1; 117997 Москва, ул. Академика Опарина, 4

irinakolyadina@yandex.comRussian Medical Academy of Postgraduate Education, Ministry of Health of RussiaФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииV.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова» Минздрава России2910202117359682910202129102021https://ojrs.abvpress.ru/ojrs/article/view/864

The article reviews studies evaluating the efficacy and safety of eribulin chemotherapy in patients with HER2-negative advanced breast cancer. It analyzes the results derived from large randomized studies, highlights the main advantages peculiar to eribulin, and describes the key mechanisms of the antitumor activity displayed by the drug. Among those presented, there are significant retrospective studies evaluating the role of eribulin chemotherapy in late and early advanced breast cancer treatment lines, as well as an analysis of surveys aimed to evaluate the efficacy of the drug in various clinical settings (for visceral metastases, brain lesion, and in elderly patients). This article reflects the main results of Russian population analyses evaluating the efficacy and safety of eribulin chemotherapy in routine clinical practice.

Представлен обзор исследований по оценке эффективности и безопасности химиотерапии эрибулином у больных HER2-отрицательным распространенным раком молочной железы. Проанализированы результаты крупных рандомизированных исследований, выделены основные преимущества эрибулина, описаны ключевые механизмы противоопухолевой активности препарата. Представлены значимые ретроспективные исследования по оценке роли химиотерапии эрибулином в поздних и ранних линиях лечения распространенного рака молочной железы, проведен анализ работ по оценке эффективности препарата в различных клинических ситуациях (при висцеральных метастазах, поражении головного мозга, у пациентов пожилого возраста). Отражены основные результаты российских популяционных анализов по оценке эффективности и безопасности химиотерапии эрибулином в рутинной клинической практике.

metastatic breast cancerlate-line chemotherapyearly-line chemotherapyeribulinvisceral metastasesbrain metastaseschemotherapy in elderly patientsRussian experience of using eribulineribulin introduced after CDK4/6 inhibitorsметастатический рак молочной железыпоздние линии химиотерапииранние линии химиотерапииэрибулинвисцеральные метастазыметастазы в головной мозгхимиотерапия у пожилых больныхроссийский опыт использования эрибулинаэрибулин после ингибиторов CDK4/6Cancer Today. Available at: https://gco. iarc.fr/today/online-analysis.Instructions for the medical use of the drug Halaven (RU LP001782 of 28.07.2012, with changes of 29.11.2018). (In Russ.).Инструкция по медицинскому применению препарата Халавен (РУ ЛП001782 от 28.07.2012, с изменениями от 29.11.2018).Cardoso F., Paluch-Shimon S., Senkus E. et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020;31(12):1623–49. DOI: 10.1016/j.annonc.2020.09.010.Zhukova L.G., Andreeva Yu.Yu., Zavalishina L.E. et al. Breast cancer. Sovremennaya onkologiya = Modern Oncology 2021;23(1):5–40. (In Russ.). DOI: 10.26442/18151434.2021.1.200823.Жукова Л.Г., Андреева Ю.Ю., Завалишина Л.Э. и др. Рак молочной железы. Современная онкология 2021;23(1): 5–40. DOI: 10.26442/18151434.2021.1.200823.Cortes J., O’Shaughnessy J., Loesch D. et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011;377:914–23. DOI: 10.1016/S0140-6736(11)60070-6.Kaufman P.A., Awada A., Twelves C. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2015;33(6):594–601.Pivot X.,Im S., Guo M. et al. Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer 2018;25(3):370–4. DOI: 10.1007/s12282-017-0826-4.Cortes J., Schoffski P., Littlefield B. Multiple modes of action of eribulin mesylate: Emerging data and clinical implication. Cancer Treat Rev 2018;70:190–8.Funahashi Y., Okamoto K., Adachi Y. et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci 2014;105(10):1334–42.Ozawa Y., Okamoto K., Adachi M. et al. Supression of metastasis and improvement of drug distribution by eribulin mesylate. Presented at: EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, November 18–21, 2014, Spain, Barcelona.Yoshida T., Ozawa Y., Kimura T. et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymalepithelial transition (MET) states. Br J Cancer 2014;110:1497–505.Dezs Z., Oestreicher J., Weaver A. et al. Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells. PLoS One 2014;9:e106131.Takaaki F., Shoko T., Yuko N. et al. Eribulin suppresses new metastases in patients with metastatic breast cancer. In Vivo 2020;34:917–21. DOI: 10.21873/invivo.11858.Garrone O., Montemurro F., Saggia Ch. et al. Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial – a multicenter retrospective study of eribulin in real life. SpringerPlus 2016;5:59. DOI: 10.1186/s40064-016-1700-0.Barni S., Fontanella C., Livraghi L. et al. A broad Italian experience with eribulin mesylate in metastatic breast cancer patients: the ESEMPiO study. Abstract e11539. DOI: 10.1200/jco.2015.33.15_ suppl.e11539.Zhao Y., Xie N., Li W. et al. Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study. Ther Adv Med Oncol 2021;13:1–13 DOI: 10.1177/17588359211030210.Adamo V., Ricciardi G., Giuffrida D. et al. Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study. Ther Adv Med Oncol 2019;11:1–7. DOI: 10.1177/1758835919895755.Krasniqi E., Pizzuti L., Valerio M. et al. Second-line eribulin in triple negative metastatic breast сancer patients. Multicentre retrospective study: The TETRIS Trial. Int J Med Sci 2021;18(10):2245–50. DOI: 10.7150/ijms.54996.Mougalian S., Kish J., Zhang J. et al. Effectiveness of eribulin in metastatic breast cancer: 10 years of real-world clinical experience in the United States. Adv Ther 2021;38:2213–25. DOI: 10.1007/s12325-020-01613-6.Inoue K., Takahashi M., Mukai H. et al. Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year postmarketing observational study in a realworld setting. Invest New Drugs 2020;38(5):1540–9. DOI: 10.1007/s10637-019-00890-546.Haeyoung K., Doo Ho Ch., Won P. et al. Prognostic factors for survivals from first relapse in breast cancer patients: analysis of deceased patients. Radiat Oncol J 2013;31(4):222–7. DOI: 10.3857/roj.2013.31.4.222.O’Shaughnessy J., Cortes J., Twelves C. et al. Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis. Sci Rep 2020;10:11203. DOI: 10.1038/s41598-020-66980-0.Kazmi S., Chatterjee D., Raju D. et al. Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine. Breast Cancer Res Treat 2020;184:559–65. DOI: 10.1007/s10549-020-05867-0.Saunus J.M., McCart Reed A.E., Leong Lim Zh., Lakhani S.R. Breast cancer brain metastases: clonal evolution in clinical context. Int J Mol Sci 2017; 18(1):152. DOI: 10.3390/ijms18010152.Fabi A., Moscetti L., Ciccarese M. et al. Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice. Future Oncol 2015;11(3):431–8. DOI: 10.2217/fon.14.271.Sirvén M., Fernández-Ortega A., Stradella A. еt al. Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center. BMC Pharmacol Toxicol 2019;20(1):68. DOI: 10.1186/s40360-019-0367-x.Fabi A., Terrenato I., Vidiri A. et al. Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial. Future Oncol 2021;17(26):3445–56. DOI: 10.2217/fon-2021-0300.Muss H., Cortes J., Vahdat L. et al. Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer Oncologist 2014;19(4):318–27. DOI: 10.1634/theoncologist.2013-0282.Martin-Babau J., Robert M., Seegers V. et al. Eribulin is safe and efficient in metastatic breast cancer in elderly patients. Results from the REPROLINE multicentric retro-prospective cohort. Available at: https://www.annalsofoncology.org/article/ S0923-7534(20)37723-1/pdf.Luca R., Alu M., Genova G. et al. Use of eribulin mesylate as second-line therapy in elderly patients with HER2 negative metastatic breast cancer (MBC): efficacy, tolerability and quality of life. Eur Rev Med Pharm Sci 2020;24:12727–34.Pedersini R., Mauro P., Amoroso V. et al. Efficacy of eribulin mesylate in older patients with breast cancer: a pooled analysis of clinical trial and real-world data. J Geriatr Oncol 2020;11(6):976–81. DOI: 10.1016/j.jgo.2020.03.021.Gorbunova V.A., Kolyadina I.V., Kovalenko E.I. et al. Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: data from many years of experience from real clinical practice in Russia. Sovremennaya onkologiya = Modern Oncology 2019;21(1):12–23. (In Russ.). DOI: 10.26442/18151434. 2019.1.190250.Горбунова В.А., Колядина И.В., Коваленко Е.И. и др. Эффективность и безопасность эрибулина при HER2-отрицательном метастатическом раке молочной железы: данные многолетнего опыта из реальной клинической практики в России. Современная онкология 2019;21(1):12–23. DOI: 10.26442/18151434. 2019.1.190250.Kolyadina I.V., Bulavina I.S., Petkau V.V. et al. Potential of using eribulin in metastatic brain lesions in breast cancer patients: scientific background and Russian clinical experience. Sovremennaya onkologiya = Modern Oncology 2019;21(2):17–24. (In Russ.). DOI: 10.26442/18151434.2019.2.190395.Колядина И.В., Булавина И.С., Петкау В.В. и др. Потенциал использования эрибулина при метастатическом поражении головного мозга у больных раком молочной железы: научные предпосылки и российский клинический опыт. Современная онкология 2019;21(2):17–24. DOI: 10.26442/18151434.2019.2.190395.Kolyadina I.V., Abidova N.R., Akopyan A.A. Analysis of the efficacy and safety of eribulin therapy in patients with HR+ HER2-negative metastatic breast cancer, pretreated with CDK4/6 inhibitors in real Russian practice. Sovremennaya onkologiya = Modern Oncology 2021;23(1):68–76. (In Russ.). DOI: 10.26442/18151434.202 1.1.200769.Колядина И.В., Абидова Н.Р., Акопян А.А. и др. Анализ эффективности и безопасности терапии эрибулином у больных HR+ HER2-негативным метастатическим раком молочной железы, предлеченных ингибиторами CDK4/6 в условиях реальной российской практики. Современная онкология 2021;23(1):68–76. DOI: 10.26442/18151434.202 1.1.200769.Mougalian S.S., Feinberg B.A., Wang E. et al. Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4/6 inhibitor therapy. Future Oncol 2019;15(34):3935–44. DOI: 10.2217/fon-2019-0537.